Abstract:Bullous pemphigoid (BP), the most common autoimmune blistering disease, is induced by autoantibodies to type XVII collagen (COL17). Previous studies demonstrated that COL17 harbors several epitopes targeted by autoreactive T and B cells and that the target epitopes change sequentially during the disease course. To elucidate the details of the humoral immune response to COL17, we used an active BP mouse model in which BP is induced by the adoptive transfer of spleen cells from wild-type mice immunized with human COL17-expressing skin grafting to immunodeficient COL17-humanized (Rag-2-/-, mouse Col17-/-, human COL17+) mice. By immunoblot analysis, antibodies to the NC16A domain and other extracellular domains (ECDs) of COL17 were detected earlier than antibodies to intracellular domains (ICDs) in the active BP model. Time course analysis by enzyme-linked immunosorbent assay demonstrated a delayed peak of antibodies to ICD epitopes in active BP model. The blockade of CD40-CD40 ligand interaction soon after the adoptive transfer suppressed the production of antibodies to the non-collagenous 16A (NC16A) domain but not to an ICD epitope, suggesting the sequential activation from T and B cells against the ECD epitopes including the NC16A domain to those against ICD epitopes in vivo. Both wild-type mice immunized with a fragment of the NC16A domain and the recipients of those spleen cells produced IgG antibodies to ICD and ECD epitopes, showing intramolecular epitope spreading from the NC16A domain to other epitopes of COL17. Furthermore, we found that a portion of the active BP model mice show intermolecular epitope spreading from human COL17 to murine BP230. The appearance of antibodies to ICD epitopes of COL17 or of antibodies to murine BP230 did not correlate with the skin changes in the mice, suggesting that those antibodies have low pathogenicity. These results suggest that the immune response to the ECD epitopes of COL17, especially to the NC16A domain, triggers intramolecular, and intermolecular epitope spreading to ICD epitopes of COL17 and to murine BP230. These novel findings provide insight into the mechanism of epitope spreading in organ-specific, antibody-mediated autoimmune disorders.

Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models

Anti-idiotypic Antibodies against BP-IgG Prevent Type XVII Collagen Depletion

Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid

IgG autoantibodies in bullous pemphigoid directly induce a pathogenic MyD88-dependent pro-inflammatory response in keratinocytes:

High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases

Immune Reaction to Type XVII Collagen Induces Intramolecular and Intermolecular Epitope Spreading in Experimental Bullous Pemphigoid Models

Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics

Elevated levels of interleukin-9 in the serum of bullous pemphigoid: possible association with the pathogenicity of bullous pemphigoid

A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets

Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity

Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption

Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption

Fc-binding proteins enhance autoantibody-induced BP180 depletion in pemphigoid

Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway

Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid

Biological treatment for bullous pemphigoid

Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Targeting antibody-mediated complement-independent mechanism in bullous pemphigoid with diacerein

Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid

Serum interleukin‐10 level is increased and correlated positively with disease severity in patients with dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid

Interleukin-36 cytokines are overexpressed in the skin and sera of patients with bullous pemphigoid